enGene (ENGN) announced that the FDA has granted Regenerative Medicine Advanced Therapy designation to detalimogene voraplasmid, the company’s investigational therapy for the treatment of high-risk, Bacillus Calmette-Guerin-unresponsive, non-muscle invasive bladder cancer with carcinoma in situ.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENGN:
- Optimistic Buy Rating for enGene Holdings Amid LEGEND Study Progress and Regulatory Advancements
- enGene price target lowered to $19 from $34 at Morgan Stanley
- enGene Holdings Reports Q2 2025 Financial Results
- enGene Holdings Approves 2025 Employee Stock Purchase Plan
- enGene Holdings Expands with New Boston Lease